


## Peginterferon/Ribavirin-Experienced, Genotype 1a Patients Without Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 1a Patients Without Cirrhosis

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASs <sup>a</sup> for elbasvir	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	8 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A

<sup>a</sup> Includes genotype 1a RASs at amino acid positions 28, 30, 31, or 93 known to confer [antiviral resistance to elbasvir](#). Baseline testing for these RASs is recommended for patients receiving elbasvir/grazoprevir-based regimens.


<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: November 6, 2019

## Peginterferon/Ribavirin-Experienced, Genotype 1a Patients With Compensated Cirrhosis


Recommended and alternative regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 1a Patients With Compensated Cirrhosis<sup>a</sup>

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASs <sup>b</sup> for elbasvir	12 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A

Recommended and alternative regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 1a Patients With Compensated Cirrhosis<sup>a</sup>

Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>c</sup>	12 weeks	I, B
ALTERNATIVE	DURATION	RATING 
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin	12 weeks	I, A

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

<sup>b</sup> Includes genotype 1a RASs at amino acid positions 28, 30, 31, or 93 known to confer [antiviral resistance to elbasvir](#). Baseline testing for these RASs is recommended for patients receiving elbasvir/grazoprevir-based regimens.


<sup>c</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

**Last update:** November 6, 2019

### Peginterferon/Ribavirin-Experienced, Genotype 1b Patients Without Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 1b Patients Without Cirrhosis

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>a</sup>	8 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A



<sup>a</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

**Last update:** November 6, 2019

## Peginterferon/Ribavirin-Experienced, Genotype 1b Patients With Compensated Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 1b Patients With Compensated Cirrhosis<sup>a</sup>

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	12 weeks	I, B
ALTERNATIVE	DURATION	RATING 
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin	12 weeks	I, A

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

**Last update:** November 6, 2019

## NS3 Protease Inhibitor + Peginterferon/Ribavirin-Experienced, Genotype 1 Patients Without Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:

## NS3 Protease Inhibitor (Telaprevir, Boceprevir, or Simeprevir) + Peginterferon/Ribavirin-Experienced, Genotype 1 Patients Without Cirrhosis

RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>a</sup>	12 weeks	IIa, B
ALTERNATIVE	DURATION	RATING
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) plus weight-based ribavirin for all genotype 1b patients, and genotype 1a patients without baseline NS5A RASs <sup>b</sup> for elbasvir	12 weeks	IIa, B
<hr/>		
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) plus weight-based ribavirin for genotype 1a patients with baseline NS5A RASs <sup>b</sup> for elbasvir	16 weeks	IIa, B
<p><sup>a</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.</p> <p><sup>b</sup> Includes genotype 1a RASs at amino acid positions 28, 30, 31, or 93 known to confer <a href="#">antiviral resistance to elbasvir</a>. Baseline testing for these RASs is recommended for patients receiving elbasvir/grazoprevir-based regimens.</p>		

**Last update:** November 6, 2019

## NS3 Protease Inhibitor + Peginterferon/Ribavirin-Experienced, Genotype 1 Patients With Compensated Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:

## NS3 Protease Inhibitor (Telaprevir, Boceprevir, or Simeprevir) + Peginterferon/Ribavirin Treatment-Experienced, Genotype 1 Patients With Compensated Cirrhosis<sup>a</sup>

RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	12 weeks	IIa, B
ALTERNATIVE	DURATION	RATING
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin	12 weeks	I, A
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) plus weight-based ribavirin for all genotype 1b patients, and genotype 1a patients without baseline NS5A RASs <sup>c</sup> for elbasvir	12 weeks	IIa, B
<hr/>		
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) plus weight-based ribavirin for genotype 1a patients with baseline NS5A RASs <sup>c</sup> for elbasvir	16 weeks	IIa, B

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

<sup>c</sup> Includes genotype 1a RASs at amino acid position 28, 30, 31, or 93 known to confer [antiviral resistance to elbasvir](#). Baseline testing for these RASs is recommended for patients receiving elbasvir/grazoprevir-based regimens.

**Last update:** November 6, 2019

## Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients Without Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:

### Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients Without Cirrhosis

RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100mg) for genotype 1a patients	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>a</sup> , regardless of subtype	12 weeks	IIa, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for genotype 1b patients	12 weeks	IIa, B
ALTERNATIVE	DURATION	RATING
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin, except in simeprevir failures	12 weeks	IIa, B

<sup>a</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

**Last update:** November 6, 2019

### Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients With Compensated Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

### Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients With Compensated Cirrhosis<sup>a</sup>

RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) for genotype 1a patients	12 weeks	I, A

Recommended regimens listed by evidence level and alphabetically for:

**Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients With Compensated Cirrhosis<sup>a</sup> **

Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup> , regardless of subtype	12 weeks	Ila, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for genotype 1b patients	12 weeks	Ila, B

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.



<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: November 6, 2019

**NS5A Inhibitor DAA-Experienced (Excluding Glecaprevir/Pibrentasvir Failures), Genotype 1 Patients, With or Without Compensated Cirrhosis**

Recommended and alternative regimens listed by evidence level and alphabetically for:

**NS5A Inhibitor DAA-Experienced (Excluding Glecaprevir/Pibrentasvir Failures), Genotype 1 Patients, With or Without Compensated Cirrhosis<sup>a</sup> **

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)	12 weeks	I, A
ALTERNATIVE	DURATION	RATING 
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup> except NS3/4 protease inhibitor inclusive DAA combination regimens	16 weeks	Ila, B

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.


<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: November 6, 2019

## Peginterferon/Ribavirin-Experienced, Genotype 2 Patients Without Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 2 Patients Without Cirrhosis

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>a</sup>	8 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A


<sup>a</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: November 6, 2019

## Peginterferon/Ribavirin-Experienced, Genotype 2 Patients With Compensated Cirrhosis

Recommended regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 2 Patients With Compensated Cirrhosis<sup>a</sup>


RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	12 weeks	I, B

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the



Recommended regimens listed by evidence level and alphabetically for:


**Peginterferon/Ribavirin-Experienced, Genotype 2 Patients With Compensated Cirrhosis<sup>a</sup> **


prescribing information.

Last update: November 6, 2019

**DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 2 Patients, With or Without Compensated Cirrhosis**

Recommended regimens listed by evidence level for:


**Sofosbuvir + Ribavirin-Experienced, Genotype 2 Patients, With or Without Compensated Cirrhosis<sup>a</sup> **


RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, B
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	12 weeks	IIb, B

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Recommended regimen for:

**Sofosbuvir + NS5A Inhibitor-Experienced (Excluding Glecaprevir/Pibrentasvir Failures), Genotype 2 Patients, With or Without Compensated Cirrhosis<sup>a</sup> **

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)	12 weeks	I, B

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

Last update: November 6, 2019

## Peginterferon/Ribavirin-Experienced, Genotype 3 Patients Without Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 3 Patients Without Cirrhosis

RECOMMENDED	DURATION	RATING <sup>i</sup>
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for patients without baseline Y93H RAS to velpatasvir <sup>a</sup>	12 weeks	I, A
ALTERNATIVE	DURATION	RATING <sup>i</sup>
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	16 weeks	IIa, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) when Y93H is present	12 weeks	IIb, B

<sup>a</sup> Baseline RAS testing for Y93H is recommended. If the Y93H substitution is identified, an alternative regimen should be used, or weight-based ribavirin should be added.



<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: November 6, 2019

## Peginterferon/Ribavirin-Experienced, Genotype 3 Patients With Compensated Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 3 Patients With Compensated Cirrhosis<sup>a</sup>

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	16 weeks	IIa, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)	12 weeks	IIb, B
ALTERNATIVE	DURATION	RATING 
Daily fixed-dose elbasvir (50 mg)/grazoprevir (100 mg) plus sofosbuvir (400 mg)	12 weeks	I, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) plus weight-based ribavirin	12 weeks	II, B

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.


<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: November 6, 2019


### DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 3 Patients, With or Without Compensated Cirrhosis

Recommended regimens by evidence level for:

### Sofosbuvir + Ribavirin-Experienced ( $\pm$ Peginterferon), Genotype 3 Patients, With or Without Compensated Cirrhosis<sup>a</sup>

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100mg)	12 weeks	I, B
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	16 weeks	IIb, B


Recommended regimens by evidence level for:


**Sofosbuvir + Ribavirin-Experienced (± Peginterferon), Genotype 3 Patients, With or Without Compensated Cirrhosis<sup>a</sup> **

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Recommended regimen for:

**DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 3 Patients, With or Without Compensated Cirrhosis<sup>a</sup> **

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)	12 weeks	I, A
<hr/>		
For patients with prior NS5A inhibitor failure and cirrhosis, addition of weight-based ribavirin is recommended.	12 weeks	IIa, C


<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

Last update: November 6, 2019

**Peginterferon/Ribavirin-Experienced, Genotype 4 Patients Without Cirrhosis**

Recommended regimens listed by evidence level and alphabetically for:

**Peginterferon/Ribavirin-Experienced, Genotype 4 Patients Without Cirrhosis**

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A

Recommended regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 4 Patients Without Cirrhosis

Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>a</sup>	8 weeks	I, B
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients who experienced virologic relapse after prior peginterferon/ribavirin therapy <sup>b</sup>	12 weeks	Ila, B
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	Ila, B

<sup>a</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.  
<sup>b</sup> If the type of prior treatment failure (relapse vs breakthrough/nonresponse) is unknown, another recommended regimen should be used.


Last update: November 6, 2019

### Peginterferon/Ribavirin-Experienced, Genotype 4 Patients With Compensated Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:		
Peginterferon/Ribavirin-Experienced, Genotype 4 Patients With Compensated Cirrhosis <sup>a</sup> ⓘ		
RECOMMENDED	DURATION	RATING ⓘ
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients who experienced virologic relapse after prior peginterferon/ribavirin therapy <sup>b</sup>	12 weeks	Ila, B
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>c</sup>	12 weeks	Ila, B
ALTERNATIVE	DURATION	RATING ⓘ
Daily ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin	12 weeks	Ila, B

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.  
<sup>b</sup> If the type of prior treatment failure (relapse vs breakthrough/nonresponse) is unknown, another recommended

Recommended and alternative regimens listed by evidence level and alphabetically for:

**Peginterferon/Ribavirin-Experienced, Genotype 4 Patients With Compensated Cirrhosis<sup>a</sup> **


regimen should be used.


<sup>c</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: November 6, 2019

**DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 4 Patients, With or Without Compensated Cirrhosis**

Recommended regimen for:

**DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 4 Patients, With or Without Compensated Cirrhosis<sup>a</sup> **

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)	12 weeks	I, A

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

Last update: November 6, 2019

**Peginterferon/Ribavirin-Experienced, Genotype 5 or 6 Patients With or Without Compensated Cirrhosis**

Recommended regimens listed by evidence level and alphabetically for:

### Peginterferon/Ribavirin-Experienced, Genotype 5 or 6 Patients, With or Without Compensated Cirrhosis<sup>a</sup>

RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup> for patients without cirrhosis	8 weeks	Ila, B
<hr/>		
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup> for patients with compensated cirrhosis	12 weeks	I, B
Daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	Ila, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	Ila, B

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: November 6, 2019

### DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 5 or 6 Patients, With or Without Compensated Cirrhosis

Recommended regimen for:


### DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 5 or 6 Patients, With or Without Compensated Cirrhosis<sup>a</sup>

RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)	12 weeks	Ila, B

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.


Last update: November 6, 2019

## Glecaprevir/Pibrentasvir Treatment Failure (All Genotypes)

Recommended regimens listed by evidence level and alphabetically for:		
Patients With Prior Glecaprevir/Pibrentasvir Treatment Failure (All Genotypes), With or Without Compensated Cirrhosis <sup>a</sup>		
RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup> plus daily sofosbuvir (400 mg) and weight-based ribavirin	16 weeks	Ila, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)	12 weeks	Ila, B
<hr/>		
For patients with compensated cirrhosis, addition of weight-based ribavirin is recommended.	12 weeks	Ila, C
<p><sup>a</sup> For <a href="#">decompensated cirrhosis</a>, please refer to the appropriate section.</p> <p><sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.</p>		

Last update: November 6, 2019

## Sofosbuvir/Velpatasvir/Voxilaprevir Treatment Failure (All Genotypes)

Recommended regimens listed by evidence level and alphabetically for:		
Patients With Prior Sofosbuvir/Velpatasvir/Voxilaprevir Treatment Failure (All Genotypes), With or Without Compensated Cirrhosis <sup>a</sup>		
RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup> plus daily sofosbuvir (400 mg) and weight-based ribavirin	16 weeks	Ila, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) plus weight-based ribavirin	24 weeks	Ila, B



Recommended regimens listed by evidence level and alphabetically for:

## Patients With Prior Sofosbuvir/Velpatasvir/Voxilaprevir Treatment Failure (All Genotypes), With or Without Compensated Cirrhosis<sup>a</sup>

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

<sup>b</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

**Last update:** November 6, 2019